Click here if this is your press release!

Ulcerative Colitis: New Healing Therapy Delivered Directly to the Gut

Written by editor

Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers, presented preclinical data from its mucosal healing program in inflammatory bowel disease (IBD) at the Crohn’s & Colitis Foundation’s IBD Innovate: Product Development in Crohn’s & Colitis® virtual conference held November 18-19, and announced its Corporate Circle membership for a three-year term.

Print Friendly, PDF & Email

SG-5-00455, the Company’s lead drug candidate from its drug and biomarker development program in IBD, could potentially be a first in class therapeutic that improves mucosal healing in IBD patients. SG-2-0776, a novel protein, was engineered into an L. lactis drug delivery system, SG-5-00455, for direct, non-systemic delivery to the gut. Mucosal healing is a key therapeutic goal for IBD and currently ranked by physicians as the top unmet need.1

The Company delivered the presentation, “Microbial proteins depleted in UC patients interact with the extracellular matrix and promote mucosal homeostasis,” during the breakout poster session on November 18.

Print Friendly, PDF & Email

About the author


Editor in chief is Linda Hohnholz.

Leave a Comment